Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Melinta Therapeutics, Inc. (NASDAQ:MLNT)

14.95
Delayed Data
As of Dec 08
 +0.05 / +0.34%
Today’s Change
10.25
Today|||52-Week Range
40.00
+6.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$157.0M

Company Description

Melinta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes antibiotics. Its product, Baxbela, is used in the treatment of acute bacterial skin and skin structure infections. The company was is headquartered in New Haven, CT.

Contact Information

Melinta Therapeutics, Inc.
300 George Street
New Haven Connecticut 06511
P:(312) 767-0291
Investor Relations:

Employees

Shareholders

Mutual fund holders0.00%
Other institutional0.00%
Individual stakeholders--

Top Executives

Daniel Mark WechslerPresident, Chief Executive Officer & Director
Paul EstremChief Financial Officer, Secretary & EVP
Sue CammarataChief Medical Officer & Executive Vice President
Erin M. DuffyChief Scientific Officer & Executive VP
John D. BluthEVP-Investor Relations & Corporate Communications